Shoeshine
|
Friday 14th November 2003 |
Text too small? |
The issues are old ones. First, the company didn't live up to the 2001 information memorandum ebitda (earnings before interest, tax, depreciation and amortisation) forecast of $18.3 million for the August 2002 year.
That's disappointing for everyone but in the context of a rocketing exchange rate, low beef prices for Tru-Test's customers and the Australian drought, it's scarcely surprising.
The Neuronz purchase has also aggravated some shareholders but, like the company's financial performance, that was known before last year's annual meeting, at which, apparently, no questions were asked.
The theory getting most traction is that someone is trying to unsettle shareholders and turn up the gas on Tru-Test's board and management to smooth the path of a takeover.
The natural candidate for the bidder is Skellmax Industries, whose largest shareholder, Axa Asia Pacific, has 5.67%.
It's a small country. Axa is also one of Tru-Test's shareholders.
No comments yet
PCT - Precinct FY26 Annual Results
PYS - Mark Samlal retires as PaySauce Director
HGH - Heartland confirms receipt of Toi Foundation approval
SCT - Scott Targets NZ$165m in Protein Revenue by FY30
KPG - Kiwi Property FY27 first quarter dividend payment
August 25th Morning Report
CNU - Board change, closing date for director nominations, & ASM
PFI - PFI Announces FY26 Annual Results
August 24th Morning Report
SKL - Shareholder Register Release